CCCarolina de Quadros Camargo

Carolina de Quadros Camargo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carolina de Quadros Camargo has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Probiotics for dementia: a systematic review and meta-analysis of randomized controlled trials

    by Jenifer F Krüger, Elaine Hillesheim, Amanda C S N Pereira, Carolina Q Camargo, Estela I Rabito

    Context: Dementia is the fifth leading cause of death in the world. Animal studies indicate that in addition to the aging process, intestinal microbiota may play an important role in the neurodegeneration process through the modulation of the gut-brain axis. Objective: A systematic review and meta-analysis was conducted to determine the effectiveness of probiotic and synbiotic supplementation on the cognitive function of individuals with dementia. Data Sources: MEDLINE, BVS, SciELO, CENTRAL, Embase, and grey literature were searched from their inception to January 2019. Study Selection: We included data from randomized clinical trials (RCTs) that addressed dementias and assessed the following outcomes: cognitive function; inflammatory, oxidative stress, and metabolic markers; nutritional status; and intestinal microbiota composition. Data Extraction: Data searches, article selection, data extraction, and risk-of-bias assessments were performed according to the Cochrane guidelines. Data were pooled by inverse-variance random-effects meta-analyses. GRADE (Grading of Recommendations Assessment, Development, and Evaluations) was used to assess the quality of evidence. Results: Data from 3 RCTs involving 161 individuals with Alzheimer’s disease receiving Lactobacillus and Bifidobacterium strains showed no beneficial effect of probiotic supplementation on cognitive function (standardized mean difference, 0.56; 95%CI: −0.06 to 1.18), with very low certainty of evidence. However, probiotic supplementation improved plasma triglycerides, very-low-density lipoprotein cholesterol, insulin resistance, and plasma malondialdehyde. No RCTs included synbiotic supplementation or assessed microbiota composition. Conclusion: Current evidence regarding the use of probiotics and synbiotics for individuals with dementia is insufficient to support their clinical application. Systematic Review Registration: PROSPERO registration no: CRD42018116148.


  • Open Access

    Pacientes sob terapia nutricional enteral e prevalência de interações fármaco-nutrientes no ambiente hospitalar

    by Jéssica Cristine Cavichiolo Kampa, Leticia de Oliveira Reis, Thais Regina Mezzomo, Carolina de Quadros Camargo

    Determinar a prevalência das possíveis interações fármaco-nutrientes em pacientes hospitalizados submetidos à terapia nutricional enteral e analisar o risco clínico. Estudo observacional, analítico e retrospectivo com prontuários de 104 pacientes em terapia nutricional enteral, internados em um hospital universitário em uma capital do sul do Brasil. Foram coletadas informações no prontuário eletrônico Tasy®, dos pacientes internados no período de julho a dezembro de 2018, que receberam terapia nutricional enteral. Os fármacos utilizados foram classificados conforme o Anatomical Therapeutic Chemical Code. As interações fármaco-nutrientes foram determinadas pelo programa Micromedex 2.0®. Dos 112 medicamentos utilizados pelos pacientes, observou-se 28,6% de potencial prevalência de interações fármaco-nutrientes, sendo 6,25% de potencial de interação fármaco com alimentos em geral e 2,7% de potencial de interação com a terapia nutricional enteral, de gravidade moderada (n = 19; 59,4%), com bom nível de evidência (n = 17; 53,2%) e de início imediato (n = 22; 68,7%). Os fármacos envolvidos foram, principalmente, a fenitoína, levotiroxina e varfarina. Os pacientes em terapia nutricional enteral apresentam pequeno mas prejudicial risco de interações fármaco-nutrientes, principalmente relacionados ao tratamento de crises convulsivas, à tireoide, e à coagulação sanguínea. Sugere-se que protocolos sejam implementados a fim de garantir segurança nutricional e medicamentosa aos pacientes hospitalizados.


  • Fish oil decreases the severity of treatment-related adverse events in gastrointestinal cancer patients undergoing chemotherapy: A randomized, placebo-controlled, triple-blind clinical trial

    by Carolina de Quadros Camargo, Michel Carlos Mocellin, Henver Simionato Brunetta, Thayz Rodrigues Chagas, Maria Emília de Souza Fabre, Erasmo Benício Santos de Moraes Trindade, Edson Luiz da Silva, Everson Araújo Nunes


  • Does l-leucine supplementation cause any effect on glucose homeostasis in rodent models of glucose intolerance? A systematic review

    by Henver S. Brunetta, Carolina Q. de Camargo, Everson A. Nunes

    L-Leucine has been used to improve metabolic outcomes in glucose-intolerant rodent models. However, because studies have used different experimental models and conditions it is difficult to establish the best approach for new clinical trials evaluating the potential effects of l-leucine on glucose homeostasis. We performed a systematic review to report the effect of l-leucine supplementation on glucose homeostasis in rodents with glucose intolerance. The search engines MEDLINE and ScienceDirect were applied using MeSH terms. Thirty-four studies were included in this systematic review. Based on the current data, ingestion of 90–140 mg day−1 of isolated l-leucine in diet-induced obesity (DIO) models shows improvement in metabolic markers if offered during the development of the metabolic disorder in almost all the studies, but not after. Branched-chain amino acid supplementation was effective in streptozotocin-induced β-cells death but not in DIO models. l-Leucine supplementation seems to have an optimal dose and timing for supplementation to improve glucose homeostasis in DIO.


  • Oral fish oil positively influences nutritional‐inflammatory risk in patients with haematological malignancies during chemotherapy with an impact on long‐term survival: a randomised clinical trial

    by T. R. Chagas, D. S. Borges, P. F. de Oliveira, M. C. Mocellin, A. M. Barbosa, C. Q. Camargo, J. Â. G. Del Moral, A. Poli, P. C. Calder, E. B. S. M. Trindade, et al.

    Background: Studies suggest that the ingestion of fish oil (FO), a source of the omega‐3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), can reduce the deleterious side‐effects of chemotherapy. The aim of this randomised clinical trial was to evaluate the effect of supplementation with oral FO for 9 weeks on nutritional parameters and inflammatory nutritional risk in patients with haematological malignancies during the beginning of chemotherapy.Methods: Twenty‐two patients with leukaemia or lymphoma were randomised to the unsupplemented group (UG) (n = 13) or supplemented group (SG) (n = 9). SG received 2 g/day of fish oil for 9 weeks. Nutritional status, serum acute‐phase proteins and plasma fatty acids were evaluated before (T0) and after (T1) the intervention period. Data were analysed using two models; model 1, comprising data from all patients included in the study, and model 2, comprising data from UG patients with no increase in the proportions of EPA and DHA in plasma and data from SG patients showing an at least 100% increase in plasma EPA and DHA.Results: SG showed an increased plasma proportion of EPA and DHA in both models. In model 2, C‐reactive protein (CRP) and CRP/albumin ratio showed larger reductions in the SG. Overall long‐term survival in both models (465 days after the start of the chemotherapy) was higher in the group ingesting fish oil (P < 0.05).Conclusions: These findings indicate an improved nutritional‐inflammatory risk and potential effects on long‐term survival in patients with haematological malignancies supplemented with FO during the beginning of chemotherapy.


  • Nutrition Risk Screening in Patients Admitted to an Adult Emergency Department of a Brazilian University Hospital

    by Akemi Arenas Kami, Ricardo Fernandes, Carolina de Quadros Camargo, Djuliana Martins Corsi, Raquel Kuerten de Salles, Erasmo Benicio Santos de Moraes Trindade

    Background: The prevalence of malnutrition in emergency units is high, and data on the nutrition risk of patients admitted in these units are scarce. The aims of this study are to determine the nutrition risk profile of individuals admitted in an emergency unit and to identify clinical, anthropometric, and laboratory attributes according to nutrition risk classification. Materials and Methods: A total of 234 individuals in an emergency unit from 1 university hospital in Brazil were enrolled in this cross‐sectional study. The nutrition risk profile was determined using the Nutrition Risk Screening 2002. Sociodemographic, clinical, anthropometric, and laboratory data were collected. Comparisons between individuals “at risk” and “not at risk” and logistic regression analyzes were performed. Results: The prevalence of nutrition risk at admission was 48.7%. Patients at risk were older (P = .031), were less educated (P = .022), had a lower body mass index (P < .001), had higher concentrations of C‐reactive protein (CRP; P = .007), had a higher CRP/serum albumin ratio (P = .004), had lower concentrations of serum albumin (P = .002), and had severe weight loss (P < .001). Altogether, this profile resulted in a longer hospital stay (P = .004), more complications (P = .005), and greater use of antibiotics (P = .024). In regression analyses, low serum albumin (odds ratio [OR], 2.75; 95% confidence interval [CI], 1.23–6.13) and, higher serum CRP (OR, 1.13; 95% CI, 1.00–3.72), use of antibiotics (OR, 13.3; 95% CI, 1.59–111.16) were predictors of long hospital stay. Conclusion: The prevalence of nutrition risk in emergency patients was high and its profile associated with worse clinical, laboratory, and anthropometric outcomes. The use of other laboratory and clinical variables may also be a good strategy for predicting adverse outcomes in emergency units.


  • A systematic review and meta-analysis of the n-3 polyunsaturated fatty acids effects on inflammatory markers in colorectal cancer

    by Michel C. Mocellin, Carolina Q. Camargo, Everson Araujo Nunes, Giovanna M.R. Fiates, Erasmo B.S.M. Trindade


  • Open Access

    Effects of mate tea consumption on muscle strength and oxidative stress markers after eccentric exercise

    by Vilma Pereira Panza, Fernando Diefenthaeler, Aline Cavalheiro Tamborindeguy, Carolina de Quadros Camargo, Bruno Monteiro de Moura, Henver Simionato Brunetta, Raphael Luiz Sakugawa, Marina Vieira de Oliveira, Emiliana de Oliveira Puel, Everson Araújo Nunes, et al.

    Dietary phytochemical supplementation may improve muscle recovery from exercise. In this study, we investigated the effect of mate tea (MT) consumption – a phenol-rich beverage – on muscle strength and oxidative stress biomarkers after eccentric exercise. In a randomised, cross-over design, twelve men were assigned to drink either MT or water (control; CON) for 11 d. On the 8th day, subjects performed three sets of twenty maximal eccentric elbow flexion exercises. Maximal isometric elbow flexion force was measured before and at 0, 24, 48 and 72 h after exercise. Blood samples were obtained before and at 24, 48 and 72 h after exercise and analysed for total phenolics, GSH, GSSG, GSH:GSSG ratio and lipid hydroperoxides (LOOH). After eccentric exercise, muscle strength was significantly reduced over time, regardless of treatments. However, MT improved the rate of strength recovery by 8·6 % on the 1st day after exercise (PPPP<0·05) but did not change over time in MT. No significant changes were observed for GSSG, GSH:GSSG ratio and LOOH levels. MT intake did not influence muscle strength at all time points assessed but hastened the strength recovery over 24 h after exercise. MT also favoured the concentration of blood antioxidant compounds.